Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

Part of paid clinical trials in Tampa, Florida.

Sponsor
Washington University School of Medicine
Study ID
NCT03141021
Status
Recruiting
Apply to this trial

Conditions

  • Malignant Peripheral Nerve Sheath Tumors

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.

Key Dates

Start date
Apr 28, 2017
Status verified
Mar 2026
Primary completion
Apr 30, 2053
Completion
Apr 30, 2053

Study Design

Enrollment
1,050 participants (estimated)

Primary Outcome Measure

Histologic characteristics of malignant peripheral nerve sheath tumor (MPNST) [ Time Frame: 10 years ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Moffitt Cancer CenterTampaFlorida33612-
Johns HopkinsBaltimoreMaryland21205
Christine Pratilas, M.D.
410-955-8751
Christine Pratilas, M.D. (PRINCIPAL_INVESTIGATOR)
National Institutes of Health (NIH)BethesdaMaryland20892
Jack F Shern, M.D.
[email protected]
301-402-1444
Jack F Shern, M.D. (PRINCIPAL_INVESTIGATOR)
Dana Farber Cancer InstituteBostonMassachusetts02215-
University of MinnesotaMinneapolisMinnesota55455-
Washington University School of MedicineSt LouisMissouri63110
Angela Hirbe, M.D., Ph.D.
[email protected]
(314) 362-8965
Angela Hirbe, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)
David Gutmann, M.D., Ph.D. (SUB_INVESTIGATOR)
Sonika Dahiya, M.D., MBBS (SUB_INVESTIGATOR)
Brian Van Tine, M.D., Ph.D. (SUB_INVESTIGATOR)
Peter Oppelt, M.D. (SUB_INVESTIGATOR)
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Ping Chi, M.D., Ph.D.
646-888-4166
Ping Chi, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)
LifespanProvidenceRhode Island02903-
University of UtahSalt Lake CityUtah84112-

Find similar trials in Tampa, FL

By research site
Moffitt Cancer Center· Tampa, FLJohns Hopkins· Baltimore, MDNational Institutes of Health (NIH)· Bethesda, MDDana Farber Cancer Institute· Boston, MAUniversity of Minnesota· Minneapolis, MNWashington University School of Medicine· St Louis, MO

Related Studies